Tech Company Financing Transactions
Rain Therapeutics Funding Round
Boxer Capital, BVF Partners and Cormorant Asset Management invested in a $63 million Series B funding round for Rain Therapeutics. The financing round was announced on 9/9/2020.
Transaction Overview
Company Name
Announced On
9/9/2020
Transaction Type
Venture Equity
Amount
$63,000,000
Round
Series B
Investors
Proceeds Purpose
Rain plans to use the proceeds to advance its pipeline of targeted cancer therapies and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
8000 Jarvis Ave. 204
Newark, CA 94560
USA
Newark, CA 94560
USA
Phone
Website
Email Address
Overview
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Avanish Vellanki
Co-Founder
Robert Doebele
Browse more venture capital transactions:
Prev: 9/9/2020: Ouster venture capital transaction
Next: 9/10/2020: Snyk venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs